Public Advisory – One lot of Jamp-Atorvastatin Calcium recalled because some bottles may be labeled as containing 10 mg tablets, but contain 40 mg tablets

ByDonald L. Leech

Aug 27, 2022

OTTAWA (ON), August 27, 2022 /CNW/ –

Summary

  • Product: Jamp-atorvastatin calcium. Some bottles may be labeled as 10mg tablets (DIN 02504197) but contain 40mg tablets.

  • Publish: Health products – Dosage
    Health products – Labeling

  • What to do: Check your bottle of Jamp-Atorvastatin Calcium 10 mg tablets to make sure it contains 10 mg tablets and not 40 mg tablets. If in doubt, contact your pharmacist to check if your bottle contains the correct tablets. If you see incorrect pills, stop taking the medicine and contact your pharmacy immediately for a replacement product. Seek immediate medical attention if you experience any serious side effects, which may include muscle pain or muscle weakness.

Pictures

Jamp-Atorvastatin Calcium 10mg Tablets (CNW Group/Health Canada)

Jamp-Atorvastatin Calcium 40mg Tablets (CNW Group/Health Canada)

Jamp-Atorvastatin Calcium 40mg Tablets (CNW Group/Health Canada)

Affected products

Product

Company

DIN

Plot

Expiration date

Jamp-Atorvastatin Calcium

10mg tablets

Jamp Pharma Corporation

02504197

D10776B

06/2023

Jamp-Atorvastatin Calcium

40mg tablets

Jamp Pharma Corporation

02504219

D10776B

06/2023

Publish

Jamp Pharma Corporation is recalling one lot (D10776B) of Jamp-Atorvastatin Calcium after discovering that a bottle labeled with Jamp-Atorvastatin Calcium 10 mg tablets contained Jamp-Atorvastatin Calcium 40 mg tablets.

Pharmacists may not recognize the error and accidentally repackage and dispense to patients bottles labeled as atorvastatin calcium 10 mg tablets (DIN 02504197), but which mistakenly contain atorvastatin calcium 40 mg tablets.

The product of the affected lot was sold to pharmacies between May 2022 and August 2022.

Atorvastatin Calcium 10 mg and 40 mg tablets are similar white, oval-shaped tablets; however, the 10 mg tablets have a “10” marked on one side while the 40 mg tablets have a “40” marked on one side.

Atorvastatin calcium is a statin class prescription medication used to lower cholesterol and other fats in the blood and for the prevention of cardiovascular diseases such as heart attacks.

Taking too much atorvastatin calcium or more than the prescribed amount for a long period of time (ie, rhabdomyolysis, a rare but serious adverse event associated with statins).

The Department is monitoring the company’s recall and will notify the public if any new health risks are identified.

what you should do

  • Check your bottle of Jamp-Atorvastatin Calcium, 10 mg tablets to make sure it contains 10 mg tablets and not 40 mg tablets. Atorvastatin calcium 10 mg tablets are white to off-white, oval shaped, film-coated tablets debossed with “10” on one side and “AT” on the other. Atorvastatin calcium 40 mg tablets are white to off-white, oval shaped, film-coated tablets debossed with “40” on one side and “AT” on the other.

  • If in doubt, contact your pharmacist to check if your Jamp-Atorvastatin Calcium bottle contains the correct tablets.

  • If you see incorrect pills, stop taking the medicine and contact your pharmacy immediately for a replacement product. Return the affected product to your pharmacy for proper disposal.

  • Seek immediate medical attention if you experience any serious side effects from atorvastatin calcium, including muscle pain or muscle weakness.

  • Contact Jamp Pharma Corporation by calling toll-free at 1-866-399-9091 ext. 501 or emailing [email protected] if you have any questions about this recall.

  • Report any health product-related adverse event or complaint to Health Canada.

Additional information for healthcare professionals:

  • Healthcare professionals, such as pharmacists, should check bottles labeled Jamp-Atorvastatin Calcium 10 mg Tablets before dispensing them to ensure that they contain the correct tablets.

  • Report any unusual package to the company, and to Health Canada.

Alert/Reminder Type: Public consultation
Category: Health products – Medicines
Published by: Health Canada

Aussi disponible en français

SOURCE Health Canada

Quote

Quote

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/August2022/27/c1224.html